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435authors suggested that either all patients above the age of 55
years or those with at least 1 risk factor should be indiscrim-
inately treated with pharmacotherapy. Nevertheless, such an
approach would result in expansion of treatment for millions
of asymptomatic men and women. Due to the considerable
potential healthcare and economic implications of the polypill
strategy, the World Health Organization, Centers for Disease
Control and Prevention, National Heart, Lung and Blood
Institute, and the Wellcome Trust have called for research to
test the impact of various polypills on CVD outcomes (3,4).
Coronary artery calcium (CAC), measured by noncontrast
cardiac computed tomography, is a well-known measure of
subclinical coronary atherosclerosis that has been well-
validated for CVD risk assessment in asymptomatic indi-
viduals (5). Higher CAC scores are directly associated with
future risk of CVD events and provide risk information that
is incremental to traditional risk factors (6). Moreover, CAC
can improve risk discrimination and reclassiﬁcation beyond
scores such as the Framingham risk score (FRS) (7,8). As
importantly, the absence of calcium is associated with an
excellent prognosis and very low event rates in asymptomatic
individuals (9,10).
We hypothesized that a simple test with a high negative
predictive value could be used to identify individuals with an
extremely low event rate, in whom indiscriminate polypill
therapy might be safely deferred. In this study, we evaluated
whether the CAC score may be used for more selective
application of the various proposed polypill strategies for
reducing CVD events.
Methods
Ethics statement. The institutional review boards at all
participating centers approved the study, and all participants
gave informed consent.Multi-Ethnic Study of 
Population at B
n = 681
Excluding Missing Covariates
N= 287
Meeting Criteria 
for Poly-Iran
n = 2278
Meeting Criteria 
for TIPS
n = 2238
Figure 1 Study Population
Flowchart of participants included in the analysis. PILL ¼ Program to Improve Life and LoMESA (Multi-Ethnic Study of
Atherosclerosis). MESA is a
National Institutes of Health/
National Heart, Lung, and Blood
Institute–funded study that was
designed to prospectively evaluate
the development and progression
of atherosclerotic disease. The
complete design and protocols
have previously been published
(11). Brieﬂy, the study included
6,814 individuals between the
ages of 45 and 84 years, from both
sexes, and free from known CVD
at baseline. The selection included patients from the resident
list of individuals from the urban areas of the recruiting centers
with emphasis on ethnic diversity.
Patient population. Using baseline data (MESA, 2000 to
2002), we identiﬁed individuals who met eligibility criteria
for 4 polypill-based published trials. The trials and criteria
used to identify individuals who may be eligible for treat-
ment with a polypill included: 1) TIPS (the Indian Polycap
Study) (12), ages 40 to 80 years without CVD and 1 CVD
risk factor; 2) Poly-Iran (13,14), ages 50 to 80 years with or
without any risk factor; 3) the initial Wald publication (2),
which suggested use by all adults above the age of 55 years;
and 4) the PILL (Program to Improve Life and Longevity)
Collaboration criteria (15), which used an FRS above 7.5%
as the inclusion criterion. Patients meeting inclusion and not
meeting exclusion criteria as detailed in those studies were
included in the present analysis (Fig. 1).
CAC score protocol. MESA participants underwent
noncontrast cardiac-gated computed tomography for CAC
score evaluation as previously described (16). ApproximatelyAtherosclerosis 
aseline: 
4
Missing Cardiovascular or Coronary Heart 
Disease Outcome n = 5
Meeting Wald’s 
Study Criteria
n = 4416
Meeting PILL 
collaboration criteria
n = 3911 
ngevity; TIPS ¼ the Indian Polycap Study.
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436one-half of the scans were performed with a 4-detector
computed tomography scanner, and electron beam tomog-
raphy was used for the remainder. The average estimated
radiation dose was 0.89 mSv. The kappa statistic was 0.92 for
agreement on the presence of CAC.
Follow-up of cardiovascular events. Participants were
followed up for a median of 7.6 years for incident CVD
events from their baseline examinations. Follow-up con-
sisted of 3 follow-up visits conducted by each participating
center. In addition, patients were contacted by telephone
every 9 to 12 months and questioned on hospital admissions,
CVD events, deaths, and outpatient diagnoses. Copies of all
medical records for all hospitalizations and outpatient
contacts that resulted in new CVD diagnoses as well as
death certiﬁcates were obtained.
Every event was adjudicated by 2 independent physicians
from the MESA events committee after review of all
medical records. Endpoints were then classiﬁed, and an
incident date was deﬁned. The classiﬁcation followed strictly
pre-deﬁned criteria. In case of discordant review, differences
were adjudicated. If differences still persisted, a ﬁnal decision
was made by the full events committee.
Coronary heart disease (CHD) events included both
myocardial infarction and death from CHD. Myocardial
infarction was deﬁned as deﬁnite, probable, or absent
based on symptoms, electrocardiographic abnormalities,
and cardiac biomarkers. CHD death was classiﬁed as
present or absent based on review of hospital records and
interview of families. A fatal CHD event was deﬁned as
a documented myocardial infarction within 28 days of
death, chest pain in the 72 h prior to death, or a history of
CHD and no other known nonatherosclerotic or noncar-
diac cause for death.
The CVD events consisted of CHD plus stroke (not tran-
sient ischemic attack), stroke death, other atherosclerotic death,
and other CVD death. A detailed description of the MESA
follow-up methods is available at www.mesa-nhlbi.org.
Statistical analysis. Baseline characteristics of the study
participants were analyzed according to the presence or
absence ofCAC. Frequencies and proportions were calculated
for categorical variables, and either mean  SD or median
(interquartile range) were calculated for continuous variables
based on normality of distribution. We used Kaplan-Meier
estimates of cumulative event-free survival to describe the
occurrence ofCHDandCVDevents over time. To determine
if CAC can further risk-stratify the individuals meeting the
criteria for polypill based on the above-mentioned studies, we
compared absolute CHD and CVD event rates as well as Cox
multivariable-adjusted hazard ratios (HRs) after stratifying by
the presence or absence of CAC. Models were adjusted for
age, sex, race/ethnicity, education level (a measure of socio-
economic status), and MESA site.
In addition, we calculated the 5-year number needed to
treat (NNT) for both CHD and CVD by applying the HR
for the expected event reduction associated with the use of
the polypill according to the TIPS study (reduction of 62%in the CHD events) (12) to the event rates at the median
follow-up for the groups with and without CAC. NNT was
calculated directly as the reciprocal of the absolute risk
difference at median follow-up of the cohort (7.6 years) based
on Kaplan-Meier estimates, and was subsequently adjusted
to a 5-year NNT according to the Altman-Anderson method
(17). A supplemental analysis of the ability of CAC to stratify
risk across different levels of clinical risk using the FRS for
each patient was performed. For this analysis, the NNTs for
5 years for CHD and CVD events were calculated for each
CAC level stratiﬁed by 3 groups of FRS deﬁned as low risk
(<10%), intermediate risk (10% to 20%), and high risk
(>20%). Sensitivity analyses were performed from a wide
range of risk reductions to evaluate the consistency of the
ﬁndings. Although some groups have proposed a reduction
in the relative risk of as high as 80%, we chose an estimate
based on the most widely accepted estimates from more
recent publications (12). Similar estimates have also
been estimated by Muntner et al. (18).Results
Baseline characteristics. Among the 6,814 individuals
initially included in MESA, 2,238 (32.8%) met the eligi-
bility criteria for TIPS, 2,278 (33.4%) for Poly-Iran, 4,416
(64.8%) were above the age of 55 years as proposed in the
initial Wald proposal, and 3,911 (57.4%) were eligible by the
PILL Collaboration criteria. The overall distribution of age,
sex, race/ethnicity, risk factors, education, baseline labora-
tory results, and CAC scores for each of the groups is pre-
sented in Table 1.
Distribution of CAC in eligible patients for each polypill
regimen. The distribution of CAC among subjects meeting
inclusion criteria for each of the 4 polypill regimens was
variable, as would be expected based on the respective
patient populations included in each study (Fig. 2). For
instance, the TIPS and the Poly-Iran studies included
younger individuals (i.e., above 40 and 50 years of age), but
excluded individuals above the age of 80 years. Additionally,
the TIPS study excluded individuals with very high
cholesterol low-density lipoprotein or elevated creatinine.
Therefore, those 2 studies resulted in a lower-risk population
and accordingly had a lower prevalence of any CAC
(i.e., CAC scores >0) as well as CAC scores >100.
Event rates by presence or absence of CAC. The rates of
CHD and CVD events stratiﬁed by the presence or
absence of CAC for each polypill study population are
presented in Table 2. The overall rates of CHD and CVD
events for patients with CAC ¼ 0 (i.e., CAC score of zero)
were low in all 4 groups, ranging from 1.2 to 1.9 CHD
events per 1,000 person-years. On the other hand, CAC
scores from 1 to 100 were associated with a 2.9- to 4.1-fold
increase in CHD events, ranging from 4.1 to 5.5 events per
1,000 person-years. For patients with a CAC score >100,
there was a 6- to 11-fold increase in the risk of CHD
events, with a rate of events ranging from 11.6 to 13.3
Table 1 Baseline Characteristics According to the Inclusion Criteria for Each Polypill Study
Characteristic TIPS (12) Poly-Iran (13,14) Wald (2)
PILL
Collaboration (15)
Number of subjects eligible in MESA 2,238 2,278 4,416 3,911
Age (yrs) 58.6  9.4 62.2  7.9 67.7  7.2 63.8  9.9
Male 1,126 (50.3%) 1,080 (47.4%) 2,094 (47.4%) 2,506 (64.1%)
Race
White 766 (34.2%) 831 (36.5%) 1,696 (38.4%) 1,385 (35.4%)
Black 573 (25.6%) 531 (23.3%) 1,250 (28.3%) 1,150 (29.4%)
Hispanic 620 (27.7%) 555 (24.4%) 931 (21.1%) 933 (23.9%)
Asian 279 (12.5%) 361 (15.8%) 539 (12.2%) 443 (11.3%)
Diabetes 191 (8.5%) 169 (7.4%) 644 (14.6%) 735 (18.8%)
Hypertension 452 (20.2%) 443 (19.5%) 2,574 (58.3%) 2,301 (58.8%)
Smoking
Never 1,062 (47.5%) 1,131 (49.8%) 2,194 (49.9%) 1,763 (45.3%)
Former 716 (32.0%) 813 (35.8%) 1,757 (39.9%) 1,517 (39.0%)
Current 457 (20.5%) 328 (14.4%) 449 (10.2%) 611 (15.7%)
Education
<High school 1,173 (53.1%) 1,182 (52.7%) 2,437 (56.2%) 2,090 (54.3%)
College 294 (13.3%) 284 (12.7%) 474 (10.9%) 477 (12.4%)
Bachelor or above 741 (33.6%) 775 (34.6%) 1,429 (32.9%) 1,279 (33.3%)
Family history of CAD 826 (39.1%) 830 (38.9%) 1,854 (45.1%) 1,650 (45.6%)
BMI (kg/m2) 28.5  5.5 27.3  5.1 28.2  5.3 29.2  5.4
LDL-C (mg/dl) 124.1  26.8 123.0  31.6 116.7  31.5 121.0  32.0
HDL-C (mg/dl) 48.8  13.9 51.9  15.3 51.7  14.9 46.2  12.1
Triglycerides (mg/dl) 115 (80–162) 110 (77–158) 111 (79–159) 126 (87–179)
Calcium scores
0 1,312 (58.6%) 1,241 (54.5%) 1,718 (38.9%) 1,596 (40.8%)
1–100 581 (26%) 628 (27.6%) 1,324 (30.0%) 1,161 (29.7%)
>100 345 (15.4%) 409 (17.9%) 1,374 (31.1%) 1,154 (29.5%)
Values are mean  SD, n (%), or mean (interquartile range).
BMI ¼ body mass index; CAD ¼ coronary artery disease; HDL-C ¼ high-density lipoprotein cholesterol; LDL-C ¼ low-density lipoprotein cholesterol;
MESA ¼ Multi-Ethnic Study of Atherosclerosis; PILL ¼ Program to Improve Life and Longevity; TIPS ¼ the Indian Polycap Study.
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437events per 1,000 person-years (Table 2). The Kaplan-
Meier estimates for CHD event–free survival for each of
the polypill populations are presented in Figure 3A.Figure 2 CAC Distribution
Distribution of coronary artery calcium (CAC) scores in each of the 4 proposed
polypill regimens. Abbreviations as in Figure 1.Similarly, among individuals with no CAC, the rate of
CVD was low across all populations, with a rate of 2.5 to 4.0
events per 1,000 person-years. For individuals with CAC
scores between 1 and 100 the rates ranged from 6.0 to 8.5
events per 1,000 person-years, whereas individuals with
a CAC score >100 had rates between 15.8 and 18.4 per
1,000 person-years. The Kaplan-Meier estimates for CVD
event–free survival for each of the polypill populations are
presented in Figure 3B.
These results remained largely unchanged after adjust-
ment for age, sex, race, education, and MESA site from
which the patient was recruited. The HRs for CAC scores
between 1 and 100 to predict CHD and CVD ranged from
2.3 to 2.8 and 1.7 to 1.9, respectively. For CAC scores
>100, the HRs for CHD and CVD ranged from 4.7 to 6.4
and 3.3 to 4.4, respectively (Table 3).
NNT according to CAC. Using the estimates of events
from the survival model at median follow-up, and assuming
the proposed beneﬁt of 62% event reduction, as per the TIPS
study (12), the NNT for 5 years to prevent 1 CVD event
would range from 81 to 130 for patients with CAC ¼ 0. For
the patients with CAC scores between 1 and 100, the NNT
would range from 38 to 54. For CAC scores>100, the NNT
to prevent 1 CVD event would be between 18 and 20 (Fig. 4).
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438Because the exact reduction in the relative risk with the
use of the polypill is not clearly deﬁned, a sensitivity analysis
was performed. For individuals with a CAC ¼ 0, the NNT
to prevent 1 CVD event over 5 years was >50 for all regi-
mens, even if the risk reduction was (unrealistically) as high
as 95%. For participants in the intermediate group, the
NNT to prevent 1 CVD event was below 50, assuming
a risk reduction of approximately 60%, as previous calcula-
tions suggest. If the beneﬁt is lower than expected, the NNT
for 5 years to prevent 1 CVD event increases and approaches
80 when the risk reduction is 40%. On the other hand, for
patients with CAC scores >100, the NNT remains favor-
able even when the risk reduction is far lower than the
estimate used in our analysis. The NNT remains below 30
when the risk reduction decreases to approximately 35% to
40% (Fig. 5).
In a subanalysis, we also assessed the utility of CAC
testing to identify groups that may beneﬁt the least and the
most from adding CAC scores to traditional risk classiﬁ-
cation by the FRS. Approximately one-third of individuals
eligible for polypill by criteria that included lower risk and
a younger population were at least intermediate risk by FRS
(TIPS ¼ 37% and Poly-Iran ¼ 40%). On the other hand,
more than 50% of individuals meeting polypill criteria
focusing on slightly older population were intermediate to
high risk (Wald ¼ 51% and PILL Collaboration ¼ 56%).
For all criteria, the NNT in those at least intermediate risk
was <48 individuals for preventing 1 CHD event and <34
individuals for preventing 1 CVD event (Online Figs. 1A
and 1B). Overall, CAC provided signiﬁcant discrimination
in the NNT to prevent CHD/CVD events in individuals
across the FRS spectrum, with the highest NNT noted
among those who have no CAC, even among the inter-
mediate-risk (NNT range 135 to 162 for hard CHD) and
high-risk (68 to 126 for hard CHD) groups. On the other
hand, among those with low FRS and CAC scores >100
across all criteria, the calculated NNT for preventing 1 hard
CHD event was 38 to 56 and was 26 to 38 for hard CVD.
Discussion
In the present study, we estimated the potential impact of
a polypill on CVD risk reduction according to CAC score in
a large, asymptomatic cohort of U.S. adults according to 4
different proposed inclusion criteria. Across subgroups that
met the inclusion and exclusion criteria for the 4 suggested
polypill regimens, the NNT in 5 years to prevent 1 CVD
event ranged from 36 to 57. However, if the strategy of
treating only individuals with CAC scores >100 is chosen,
the majority of persons who experienced events would be
eligible for therapy, but the overall population requiring
treatment would be less than one-third of the initial sample
in any of the 4 strategies. Accordingly, the NNT for 5 years
to reduce 1 CVD event decreased to 18 to 20, which is much
lower than the threshold used to recommend the treatment
of hypertension (19,20) or for the use of statins in primary
AB
Figure 3 Survival Free From Events According to CAC Scores
(A) Survival free from coronary heart disease (CHD) events stratiﬁed by the presence or absence of CAC for each of the 4 polypill regimens. (B) Survival free from cardiovascular
disease (CVD) events stratiﬁed by the presence or absence of CAC for each of the 4 polypill regimens. Abbreviations as in Figures 1 and 2.
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439prevention (21,22). On the other extreme, the group with
CAC ¼ 0 had much higher NNT, ranging from 81 to 130.
In this group, the strategy of prescribing the polypill would
result in an extremely low, if any, net beneﬁt.
Notably, our sensitivity analysis afﬁrms that the beneﬁts
of treating individuals with CAC scores >100 are extremelyrobust, as even if the actual efﬁcacy of the polypill were one-
half of expected, treating this population would still result in
a highly favorable NNT. The results of the sensitivity
analysis showing the lack of expected beneﬁt for the group
with CAC ¼ 0 are also robust. This group has such a low
event rate in 7.6 years of follow-up that even if the reduction
Table 3 HRs (95% CIs) for CHD and CVD Events With Increasing Burden of CAC for the Polypill Studies
TIPS (12) Poly-Iran (13,14) Wald (2) PILL Collaboration (15)
HR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value
CHD
CAC ¼ 0 1.0 (ref) d 1.0 (ref) d 1.0 (ref) d 1.0 (ref) d
CAC 1–100 2.7 (1.2–5.8) 0.014 2.4 (1.1–5.1) 0.022 2.3 (1.4–3.8) 0.002 2.8 (1.6–4.8) <0.0001
CAC >100 6.4 (2.9–13.8) <0.0001 5.9 (2.8–12.2) <0.0001 4.7 (2.9–7.6) <0.0001 5.6 (3.3–9.5) <0.0001
CVD
CAC ¼ 0 1.0 (ref) d 1.0 (ref) d 1.0 (ref) d 1.0 (ref) d
CAC 1–100 1.7 (0.9–3.1) 0.076 1.9 (1.1–3.4) 0.031 1.9 (1.3–2.7) 0.001 1.8 (1.2–2.7) 0.002
CAC >100 4.4 (2.4–7.8) <0.0001 4.2 (2.4–7.4) <0.0001 3.3 (2.3–4.7) <0.0001 3.3 (2.3–4.8) <0.0001
Values are hazard ratio (HR) (95% conﬁdence interval [CI]). The results are adjusted for age, sex, race, education, and MESA site.
Abbreviations as in Tables 1 and 2.
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440in the relative risk were as high as 95%, the beneﬁt would be
minimal. Finally, the group with CAC between 1 and 100 is
most sensitive to the potential beneﬁt of the polypill. If the
actual beneﬁt were as high as the 80%, as initially proposed
(2), this group will have a favorable NNT between 29 and 40
and is thus likely to beneﬁt. On the other hand, if the actual
risk reduction were still around 50%, the expected NNT
would be as high as 65.
Irrespective of which of the 4 sets of inclusion criteria is
used, our current data support the use of a single measure of
the CAC to improve risk stratiﬁcation among the pop-
ulation considered eligible for primary prevention with the
polypill. If only individuals with CAC >100 were treated,
the treated population would be reduced by more than 60%,
while about 60% of the individuals who develop an event
would still receive treatment. The hypothesis that CAC
testing may be able to more appropriately identify those who269
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Figure 4 NNT According to CAC Scores
Number needed to treat (NNT) to prevent 1 CHD (left) and 1 CVD (right) event in 5 year
directly as the reciprocal of the absolute risk difference at the median follow-up of 7.6 years a
abbreviations as in Figures 1 and 3.will not beneﬁt from polypill therapy is also supported by our
recent ﬁndings MESA participants meeting the JUPITER
(Justiﬁcation of the Use of Statins in Primary Prevention: an
Intervention Trial Using Rosuvastatin) criteria for statin
therapy (23), in which we showed that among the 47% of
the population with CAC ¼ 0, there was an extremely low
event rate with a corresponding NNT of 549.
Our results provide important insight regarding a key
question in primary prevention: should we “treat all” at-risk
individuals or instead use a more targeted approach of
treating only individuals with evidence of establisheddalbeit
subclinicalddisease. The initial publication on the polypill
suggested that “a large preventive effect would require
intervention in everyone at increased risk, irrespective of the
risk factor levels” (2). At the time, the authors suggested that
anyone above the age of 55 years would be an appropriate
candidate. Our study and others (24) support the notion that130 130
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s using the entry criteria for each of the polypill regimen. The NNTs were calculated
nd were subsequently adjusted to a 5-year period. CAC¼ coronary artery calcium; other
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Figure 5 Sensitivity Analysis for the NNT
Sensitivity analysis for the NNT for 5 years to reduce 1 CVD event. The curves
represent the NNT values across the spectrum of reductions in the relative risk
with the use of the polypill in each study. (A) Subjects with a CAC score of 0. (B)
Subjects with CAC scores 1 to 100. (C) Subjects with CAC scores >100. The
lower panel includes a red reference line on the NNT of 30 for reference.
Abbreviations as in Figures 1, 3, and 4.
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441treatment based on CAC may identify a larger proportion of
individuals at risk for events than other approaches that are
based on age or risk factors.
Our analysis demonstrated that even after taking addi-
tional risk stratiﬁcation with global risk scores such as FRS,
among the population considered eligible for the polypill
based on pre-deﬁned risk factor–based criteria, CAC was
still able to provide clinically-meaningful information toguide treatment. Among individuals considered to be at
intermediate to high risk, the absence of CAC was associ-
ated with a considerably higher NNT to prevent 1 cardiac
event. Based on our secondary analyses, we believe there is
strong value in using the combination of clinical scores and
CAC scores for identifying appropriate groups among
whom we may expect the greatest beneﬁt from initiation of
polypill, along with identifying subgroups among whom the
beneﬁt may be limited. For example, if one decides that the
acceptable NNT for CVD for polypill is 30 to 40, among the
individuals who would be candidates for the Wald regimen,
only those with CAC scores >100 or the high FRS with
CAC scores >0 would be the most appropriate group that is
likely to derive the greatest beneﬁt from the polypill.
However, in the same process, the initial candidate pop-
ulation could be reduced by 64% (from 4,416 to 1,617
individuals requiring treatment) and, as a result, could have
tremendous impact when the proposal of widespread use of
the polypill is considered.
The use of CAC for screening for coronary atheroscle-
rosis has some disadvantages. First, although the radiation
dose is lower than 1 mSV (approximately equivalent to
a bilateral mammogram), this poses a small theoretical risk
(25). Second, CAC progresses over time and the actual
“warranty period” of having no CAC is not completely
clear but is likely to approach at least 4 to 5 years (26).
Finally, the polypill is expected to be an intervention that
would be able to prevent CVD events at a low cost. CAC
scanning is associated with a small additional cost (Euro-
pean costs are approximately V115 [27]; however, because
the cost is mainly driven by human resources, the cost is
expected to be lower in developing countries). Further
studies regarding the cost-effectiveness of CAC screening
followed by selective treatment versus a treat-all approach
are warranted (28). Importantly, CAC scoring can be
performed on the vast majority of the currently-available
scanners around the world, and this technology will be
neither a signiﬁcant limitation nor responsible for increased
costs.
It is noteworthy that the polypill is still under evaluation
and also has some undeﬁned limitations. First, because
a single combined pill formulation is proposed, individuals
with a contraindication to any of the components would
not be eligible. For instance, individuals with asthma
(a contraindication to beta-blockers) or aspirin intolerance
may not tolerate such therapy. Second, there is a signiﬁcant
rate of discontinuation due to side effects from the polypill.
Although not signiﬁcantly higher than placebo in short-term
follow-up studies, up to 36% of patients discontinued
treatment due to reported side effects in a recent meta-
analysis of polypill studies (29).
Our analysis does not address the potential harm of
treatment with the polypill. Although no data are yet
available for the polypill, vast literature on the side effects of
many of the individual drugs is available. One large database
study presented observational data that suggested that the
Bittencourt et al. JACC Vol. 63, No. 5, 2014
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442numbers needed to harm with 5 years of treatment with
statins are variable, but can be as low as 136 for liver
dysfunction, 91 for myopathy, and 346 for acute renal failure
(29). Additionally, another large study evaluated the risk of
bleeding in a cohort of patients taking aspirin and found
a particularly important increase in the risk of bleeding in
nondiabetics, similar to the population included in our
study. The use of aspirin increased the incidence rate of
bleeding by approximately 2.0 events per 1,000 person-years
(30). These results are particularly concerning when
considering that individuals with a CAC ¼ 0 had very low
CVD rates of 2.5 to 4.0 per 1,000 person-years in our study
and are thus more likely to be harmed by therapy.
Study limitations. An important limitation of our study is
that the long-term efﬁcacy of the polypill remains to be
proven. The various therapies (e.g., aspirin, statins) have
individually reduced events in primary prevention trials, and
thus although the exact magnitude of the combined beneﬁt
is unknown, it is fair to state that some beneﬁtdeven if
lower than predicted by Yusuf et al. (12)dwill likely be
realized by this strategy. Nevertheless, given the fact that the
precise beneﬁt is unknown, we performed a sensitivity
analysis that afﬁrmed the ﬁnding that once CAC is present,
and particularly when CAC scores are >100, the favorably
low NNT will persist across a wide range of risk reduction.
Our study evaluated various polypill studies with different
inclusion criteria, but we did not aim to compare them.
Rather, by presenting the full spectrum of all suggested pol-
ypill regimens, our aim was to test how robustly CAC scoring
may perform in identifying groups who are most likely to
beneﬁt from therapy. In this sense, the current data support
the presence of calcium as a simple and accurate tool for the
selection of patients most likely to beneﬁt from the polypill.
Conclusions
CAC has the potential to identify patients most likely to
receive net beneﬁt from the polypill. Such an approach would
signiﬁcantly reduce the number of individuals requiring
treatment, thus reducing important side effects and cost, but
would still ensure treatment in the majority of individuals
who are likely to experience CHD and CVD events.
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